Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization.
Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization.
复制标题
DOI:
10.1038/s42003-021-02728-4
复制
发表时间:
2021-10-13
影响因子:
5.9
通讯作者:
Wang Y
中科院分区:
文献类型:
--
作者:
Zhang L;Cui Z;Li Q;Wang B;Yu Y;Wu J;Nie J;Ding R;Wang H;Zhang Y;Liu S;Chen Z;He Y;Su X;Xu W;Huang W;Wang Y
Emerging mutations in SARS-CoV-2 cause several waves of COVID-19 pandemic. Here we investigate the infectivity and antigenicity of ten emerging SARS-CoV-2 variants—B.1.1.298, B.1.1.7(Alpha), B.1.351(Beta), P.1(Gamma), P.2(Zeta), B.1.429(Epsilon), B.1.525(Eta), B.1.526-1(Iota), B.1.526-2(Iota), B.1.1.318—and seven corresponding single amino acid mutations in the receptor-binding domain using SARS-CoV-2 pseudovirus. The results indicate that the pseudovirus of most of the SARS-CoV-2 variants (except B.1.1.298) display slightly increased infectivity in human and monkey cell lines, especially B.1.351, B.1.525 and B.1.526 in Calu-3 cells. The K417N/T, N501Y, or E484K-carrying variants exhibit significantly increased abilities to infect mouse ACE2-overexpressing cells. The activities of furin, TMPRSS2, and cathepsin L are increased against most of the variants. RBD amino acid mutations comprising K417T/N, L452R, Y453F, S477N, E484K, and N501Y cause significant immune escape from 11 of 13 monoclonal antibodies. However, the resistance to neutralization by convalescent serum or vaccines elicited serum is mainly caused by the E484K mutation. The convalescent serum from B.1.1.7- and B.1.351-infected patients neutralized the variants themselves better than other SARS-CoV-2 variants. Our study provides insights regarding therapeutic antibodies and vaccines, and highlights the importance of E484K mutation. Li Zhang, Zhimin Cui, and Qianqian Li et al. compare the infectivity, host tropism, and antigenicity of 10 SARS-CoV-2 variants using a VSV-based pseudovirus system. Their results suggest that variants carrying E484K display the most significant reduction in sensitivity to neutralization, and may provide further insight into the development of relevant therapeutics for SARS-CoV-2 infection.
登录
查看更多内容
DOI:
10.1016/s2468-2667(21)00055-4
发表时间:
2021-05
期刊:
The Lancet. Public health
影响因子:
--
作者:
Graham MS;Sudre CH;May A;Antonelli M;Murray B;Varsavsky T;Kläser K;Canas LS;Molteni E;Modat M;Drew DA;Nguyen LH;Polidori L;Selvachandran S;Hu C;Capdevila J;COVID-19 Genomics UK (COG-UK) Consortium;Hammers A;Chan AT;Wolf J;Spector TD;Steves CJ;Ourselin S
通讯作者:
Ourselin S
DOI:
10.1126/science.abg3055
发表时间:
2021-04-09
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Davies NG;Abbott S;Barnard RC;Jarvis CI;Kucharski AJ;Munday JD;Pearson CAB;Russell TW;Tully DC;Washburne AD;Wenseleers T;Gimma A;Waites W;Wong KLM;van Zandvoort K;Silverman JD;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium;Diaz-Ordaz K;Keogh R;Eggo RM;Funk S;Jit M;Atkins KE;Edmunds WJ
通讯作者:
Edmunds WJ
影响因子:
64.5
作者:
Li Q;Nie J;Wu J;Zhang L;Ding R;Wang H;Zhang Y;Li T;Liu S;Zhang M;Zhao C;Liu H;Nie L;Qin H;Wang M;Lu Q;Li X;Liu J;Liang H;Shi Y;Shen Y;Xie L;Zhang L;Qu X;Xu W;Huang W;Wang Y
通讯作者:
Wang Y
DOI:
10.1016/s0140-6736(21)00183-5
发表时间:
2021-02-06
期刊:
Lancet (London, England)
影响因子:
--
作者:
Sabino EC;Buss LF;Carvalho MPS;Prete CA Jr;Crispim MAE;Fraiji NA;Pereira RHM;Parag KV;da Silva Peixoto P;Kraemer MUG;Oikawa MK;Salomon T;Cucunuba ZM;Castro MC;de Souza Santos AA;Nascimento VH;Pereira HS;Ferguson NM;Pybus OG;Kucharski A;Busch MP;Dye C;Faria NR
通讯作者:
Faria NR
DOI:
10.1126/science.abe5901
发表时间:
2021-01-08
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Oude Munnink BB;Sikkema RS;Nieuwenhuijse DF;Molenaar RJ;Munger E;Molenkamp R;van der Spek A;Tolsma P;Rietveld A;Brouwer M;Bouwmeester-Vincken N;Harders F;Hakze-van der Honing R;Wegdam-Blans MCA;Bouwstra RJ;GeurtsvanKessel C;van der Eijk AA;Velkers FC;Smit LAM;Stegeman A;van der Poel WHM;Koopmans MPG
通讯作者:
Koopmans MPG